Utah is currently home to 1198 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823
Recruiting
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Paravalvular Aortic Regurgitation
Register for Updates
Standard Versus High Dose ED-Initiated Buprenorphine Induction
NCT06494904
Recruiting
This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/23/2025
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Opioid Use Disorder
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
SAfety of Regional Citrate Anticoagulation (SARCA Study)
NCT05339139
Recruiting
This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Intermountain Health, Murray, Utah
Conditions: Acute Kidney Injury, ESRD
Register for Updates
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: St. George Eye Center /ID# 236200, Saint George, Utah
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
NCT04469439
Recruiting
This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do not undergo surgery but are treated medically for CRS will also be enrolled to serve as a control group. Outcomes analyzed will include pulmonary, quality of life, and others.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/23/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
Register for Updates
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075
Recruiting
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/22/2025
Locations: Advanced Research Institute, Ogden, Utah
Conditions: Acute Migraine
Register for Updates
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
NCT06605118
Recruiting
This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/22/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Register for Updates
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT06400472
Recruiting
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: START Mountain Region, West Valley City, Utah
Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Register for Updates
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
NCT05154994
Recruiting
This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Register for Updates
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04754191
Recruiting
This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer. The trial will open to enrollment in Cohort A, enfortumab monotherapy. Additional cohorts may be added as new drug combinations are identified.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: Utah Blood and Marrow Transplant Program-Peds, Salt Lake City, Utah
Conditions: SCID
Register for Updates